Sanofi-Aventis Rebates Aim To Accelerate Switch To Ambien CR
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm is offering concessions to U.S. healthcare providers to switch patients to the extended-release formulation.
You may also be interested in...
Sanofi Suit Triggers 30-Month Stay Of FDA Action On Barr’s Ambien CR ANDA
Sanofi-Aventis filed a patent infringement suit against Barr on April 5 over the controlled release form of zolpidem.
Sanofi Suit Triggers 30-Month Stay Of FDA Action On Barr’s Ambien CR ANDA
Sanofi-Aventis filed a patent infringement suit against Barr on April 5 over the controlled release form of zolpidem.
Leave It To Beaver: Rozerem DTC Campaign Boosts New Rx Share
Takeda sleep aid’s new Rx share has grown more than 50% since campaign began.